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(range 28-87%). The median decrease in V20 in the replan was 8.4% 
(range 3.3-22.5%), resulting in a decrease of V20 of 1.7% (range 0.5-
5.1%) in the composite. For V5, V10, V30, and V45, replans showed 
a median improvement of 13.7% (range 0.7-43%), 11.0% (range 
0.2-33.4%), 9.0% (range 4.9-10.9%), and 4.6% (range 3.8-13.1%), 
respectively. Heart volumes at 40 Gy improved by 0.8% (range 0-
14.5%). The greatest improvements were seen in esophagus volumes at 
50 Gy, which improved by 28.6% (range 0-66.8%), for an improvement 
of 23% in the composite plan. In patients receiving higher doses, V60 
and V65 improved by 4.0% (range 0-11.2%) and 0.2% (range 0-5.9%), 
respectively. At a median follow-up of 4.2 months, no patient had local 
or distant relapse.
Conclusions: Small cell lung cancer planning target volumes can 
decrease by half during a deﬁnitive chemoradiation treatment course. 
Resimulation and replanning reduces the volumes of normal lung 
treated for the last third of the course. Volumes of heart and esophagus 
at tolerance doses are also reduced. At early follow-up, mid-course 
resimulation does not compromise local control.
Figure 1: Dose-volume histogram for original radiotherapy plan (thick line) 
versus second plan (thin line) and composite plan incorporating resimulation 
volumes (dashed).
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Introduction: UCN-01 inhibits several serine-threonine kinases, 
causes arrest of cell cycle progression at G1/S phase, induces apoptosis 
of SCLC cell lines, and has shown synergistic activity with topotecan. 
Phase II doses of UCN-01 in combination with topotecan had been 
previously determined in another PMH-C study. The objective of the 
current study was to determine the antitumor activity of UCN-01and 
topotecan in pts with SCLC relapsing more than 3 months after the 
completion of ﬁrst-line platinum-based combination chemotherapy. 
Methods: Eligibility criteria included: age > 18, ECOG PS 0-2, 1 prior 
platinum-based chemotherapy regimen completed at least 3 months 
prior to enrollment. Pts with coronary artery disease, a requirement for 
insulin, or prior topoisomerase I inhibitor were excluded. Pts received 
UCN-01 70 mg/m2 (cycle 1) or 35 mg/m2 (cycles 2+) IV day 1 plus 
topotecan 1 mg/m2 IV days 1-5 q21 days. Response was assessed by 
RECIST every 2 cycles. A two-stage design was used; if at least 4 
responses were seen in the ﬁrst 17 evaluable pts; the cohort would be 
expanded. 
Results: 17 pts have been enrolled over 24 months, 1 never received 
treatment due to CNS disease. Of 16 eligible patients, 9 are female, 
15 PS 0/1, median age 57 [range 50-73], median time from ﬁrst line 
therapy = 6.5months). Median number of cycles = 4 (range 1 -6). Com-
mon grade 3/4 toxicities: leukopenia (73% of patients) neutropenia (67 
%), lymphopenia (47%), thrombocytopenia (33 %), hyponatremia (27 
%), fatigue (27 %), pneumonia (20%). There were 3 serious adverse 
events: grade 3 pneumonia (1) and febrile neutropenia (2). Antitumor 
activity: PR = 1; SD = 7; Progression = 7; too early=1. 
Conclusions: This combination appears well-tolerated, but does not 
appear more active than standard single-agent topotecan. The study 
does not fulﬁll criteria to proceed to stage 2. 
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Background: The treatment of patients with limited disease small cell 
lung cancer (LD-SCLC) consists of concurrent chemo-radiotherapy, 
at the expense of dose-limiting acute esophagitis and lung damage. A 
straightforward strategy to reduce toxicity is to diminish the radiation 
ﬁelds. In NSCLC, radiation ﬁelds could be safely reduced by selective 
nodal irradiation, based on CT, and even further based on FDG-PET 
scans. However, in a phase II study in LD-SCLC, we observed 11% of 
isolated nodal failures. As literature suggests that also in SCLC, PET 
scan is more accurate than CT in identifying regional lymph nodes, 
we hypothesized that in patients with LD-SCLC, there would be less 
geographical miss by using PET scans compared to CT and hence there 
would be changes in the radiation exposure of normal tissues. 
Methods: Twenty-one consecutive patients with LD-SCLC were stud-
ied. For each patient, two three-dimensional conformal treatment plans 
were made where only the pathological lymph nodes were included in 
the GTV, either based on CT or on PET scan, both to a dose of 45 Gy 
in 30 fractions (1,5 Gy BID). The dosimetric factors associated with 
lung (MLD: Mean Lung Dose; V20) and esophageal toxicity (Dmax: 
maximal esophageal dose; MED: Mean Esophageal Dose) were ana-
lyzed and compared. All values are expressed as mean±SD. Wilcoxon’s 
signed rank test was used to compare differences.
